Table 2.
Relative survival (RS) rate and Excess mortality rate ratio (EMRR) with 95 % CI for ILC compared with IDC estimated from univariable Poisson regression.
| Years after diagnosis | Number at risk at start of interval |
RS (%) and (95% CI) at the end of interval |
EMRR ILC vs IDC (95% CI) | P value | |||
|---|---|---|---|---|---|---|---|
| ILC | IDC | ILC | IDC | ||||
| All | 0–5 | 2898 | 14,583 | 93 (92–94) | 90 (89–90) | 0.64 (0.53–0.77) | <0.001 |
| 5–10 | 2591 | 12,595 | 85 (83–87) | 82 (82–83) | 1.09 (0.91–1.32) | 0.35 | |
| 10–15 | 2207 | 10,892 | 78 (76–80) | 78 (77–79) | 1.49 (1.16–1.93) | 0.002 | |
| 15–20 | 1607 | 8413 | 72 (69–75) | 73 (72–75) | 1.35 (0.88–2.07) | 0.17 | |
| ER+ | 0–5 | 2117 | 9263 | 93 (92–95) | 93 (92–94) | 0.97 (0.78–1.21) | 0.78 |
| 5–10 | 1894 | 8273 | 85 (83–87) | 85 (84–86) | 1.07 (0.86–1.33) | 0.57 | |
| 10–15 | 1617 | 7126 | 78 (75–80) | 79 (78–81) | 1.39 (1.05–1.84) | 0.02 | |
| ER- | 0–5 | 201 | 2719 | 87 (81–92) | 75 (74–77) | 0.46 (0.29–0.73) | 0.001 |
| 5–10 | 169 | 1982 | 74 (67–81) | 68 (66–69) | 1.27 (0.75–2.17) | 0.38 | |
| 10–15 | 136 | 1692 | 69 (60–77) | 64 (62–67) | 1.47 (0.51–4.21) | 0.48 | |
| ER+/PR+ | 0–5 | 1654 | 7226 | 93 (92–95) | 94 (94–95) | 1.21 (0.94–1.57) | 0.14 |
| 5–10 | 1485 | 6562 | 85 (83–88) | 87 (86–88) | 1.09 (0.85–1.40) | 0.49 | |
| 10–15 | 1277 | 5691 | 78 (76–81) | 81 (80–82) | 1.26 (0.91–1.75) | 0.16 | |
| ER+/PR- | 0–5 | 451 | 1985 | 93 (90–96) | 87 (86–89) | 0.55 (0.35–0.88) | 0.01 |
| 5–10 | 399 | 1662 | 83 (79–88) | 78 (76–81) | 0.99 (0.63–1.55) | 0.96 | |
| 10–15 | 330 | 1392 | 74 (68–80) | 73 (70–76) | 1.70 (0.95–3.05) | 0.08 | |
| NHG I | 0–5 | 362 | 2185 | 96 (92–98) | 99 (98–99) | 2.57 (1.02–6.44) | 0.04 |
| 5–10 | 332 | 2076 | 91 (86–95) | 96 (95–98) | 2.47 (1.01–6.03) | 0.05 | |
| 10–15 | 295 | 1917 | 83 (76–88) | 93 (91–95) | 3.82 (1.78–8.20) | 0.001 | |
| NHG II | 0–5 | 1295 | 3366 | 96 (94–97) | 94 (93–95) | 0.77 (0.54–1.12) | 0.18 |
| 5–10 | 1190 | 3047 | 89 (86–91) | 87 (85–88) | 0.90 (0.64–1.26) | 0.54 | |
| 10–15 | 1039 | 2654 | 83 (80–86) | 82 (80–84) | 1.16 (0.71–1.91) | 0.55 | |
| NHG III | 0–5 | 133 | 2552 | 78 (69–84) | 82 (80–83) | 1.22 (0.82–1.81) | 0.33 |
| 5–10 | 100 | 2019 | 65 (55–73) | 71 (69–73) | 1.32 (0.74–2.36) | 0.35 | |
| 10–15 | 79 | 1691 | 61 (50–70) | 66 (63–68) | 0.80 (0.20–3.16) | 0.75 | |
| Age | 0–5 | 583 | 3788 | 92 (90–94) | 87 (86–88) | 0.58 (0.42–0.80) | 0.001 |
| < 50 | 5–10 | 534 | 3285 | 82 (79–85) | 78 (76–79) | 0.96 (0.71–1.28) | 0.77 |
| 10–15 | 470 | 2882 | 73 (69–76) | 72 (71–74) | 1.78 (1.28–2.48) | 0.001 | |
| Age | 0–5 | 1336 | 6712 | 94 (92–95) | 91 (90–91) | 0.66 (0.51–0.87) | 0.002 |
| 50–64 | 5–10 | 1217 | 5915 | 87 (84–89) | 84 (83–85) | 1.07 (0.80–1.43) | 0.64 |
| 10–15 | 1084 | 5293 | 80 (77–83) | 81 (80–82) | 1.87 (1.32–2.66) | <0.001 | |
| Age | 0–5 | 979 | 4083 | 94 (91–96) | 91 (89–92) | 0.72 (0.49–1.06) | 0.09 |
| ≥ 65 | 5–10 | 840 | 3395 | 84 (80–88) | 84 (82–86) | 1.37 (0.92–2.03) | 0.12 |
| 10–15 | 653 | 2717 | 78 (73–83) | 78 (75–80) | 0.93 (0.46–1.86) | 0.83 | |
| T size | 0–5 | 500 | 3434 | 98 (95–100) | 98 (97–99) | 1.02 (0.38–2.77) | 0.97 |
| ≤ 10 mm | 5–10 | 467 | 3224 | 96 (92–99) | 95 (94–97) | 1.17 (0.37–3.69) | 0.78 |
| 10–15 | 425 | 2941 | 93 (87–97) | 93 (91–95) | 1.12 (0.25–5.14) | 0.88 | |
| T size | 0–5 | 1196 | 6199 | 97 (95–98) | 93 (92–94) | 0.42 (0.25–0.70) | 0.001 |
| 11–20 | 5–10 | 1111 | 5550 | 90 (88–93) | 87 (85–88) | 0.96 (0.68–1.36) | 0.84 |
| Mm | 10–15 | 967 | 4861 | 84 (81–87) | 82 (80–83) | 1.40 (0.92–2.13) | 0.12 |
| T size | 0–5 | 1118 | 4623 | 87 (85–90) | 79 (78–80) | 0.57 (0.46–0.69) | <0.001 |
| >20 mm | 5–10 | 939 | 3530 | 75 (72–78) | 67 (65–69) | 0.93 (0.74–1.16) | 0.52 |
| 10–15 | 757 | 2833 | 65 (62–69) | 61 (59–62) | 1.26 (0.91–1.74) | 0.16 | |
CI: Confidence interval, EMRR: Excess mortality rate ratio, ER: Estrogen receptor, IDC: Invasive ductal carcinoma, ILC: Invasive lobular carcinoma, NHG: Nottingham histologic grade, PR: Progesterone receptor, RS: Relative survival, T size: Tumour size.